Tidemark’s Intellia Therapeutics NTLA Stock Holding History

Tidemark’s Portfolio NTLA Stock Details NTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.67K	Hold	158	–	–	﹤0.01%	666
2026 Q1	$2.03K	Buy	+158	New	+$2.01K	﹤0.01%	656

Other funds holding NTLA

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return

Tidemark's NTLA Position: Q2 2026 in Review

Tidemark held its Intellia Therapeutics (NTLA) position steady in Q2 2026 at 158 shares worth $2.67K. The position accounts for ﹤0.01% of the portfolio, ranked #666.

Tidemark first reported a position in NTLA in Q1 2026 and has held it in 2 quarters since. 328 funds tracked by Wall St. Rank hold NTLA as of Q2 2026.

Tidemark held 158 shares of Intellia Therapeutics worth $2.67K as of Q2 2026.
Tidemark left its Intellia Therapeutics share count unchanged in Q2 2026.
Intellia Therapeutics made up ﹤0.01% of Tidemark's portfolio in Q2 2026, its #666 holding.
Tidemark first reported a position in Intellia Therapeutics in Q1 2026 and has held it in 2 quarters since.
328 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2026.

Based on Tidemark's 13F filing for Q2 2026, filed 10 Aug 2026.